Shire/Baxalta Merger's Benefits Doubted By Wall Street

The successful culmination of Shire PLC's months-long pursuit of Baxalta Inc. to create the world's biggest rare disease company generally was seen as a good thing by analysts, but they question how much value acquiring the Baxter International Inc. spinout for approximately $32bn truly will bring to the Irish specialty pharma. Concerns center on the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.